Abnormal Development - Hypertension - Revision history

Z8600021 at 00:19, 4 December 2019

2019-12-04T00:19:20Z

← Older revision		Revision as of 10:19, 4 December 2019
Line 31:		Line 31:
	\| [[File:Mark_Hill.jpg\|90px\|left]] {{Most_Recent_Refs}}		\| [[File:Mark_Hill.jpg\|90px\|left]] {{Most_Recent_Refs}}

	Search term: [http://www.ncbi.nlm.nih.gov/pubmed/?term=Maternal+Hypertension ''Maternal Hypertension''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Gestational+Hypertension ''Gestational Hypertension''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Preeclampsia ''Preeclampsia''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Eclampsia ''Eeclampsia''] [http://www.ncbi.nlm.nih.gov/pubmed/?term=Gestational+Methyldopa ''Gestational Methyldopa'']		Search term: [http://www.ncbi.nlm.nih.gov/pubmed/?term=Maternal+Hypertension ''Maternal Hypertension''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Gestational+Hypertension ''Gestational Hypertension''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Preeclampsia ''Preeclampsia''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Pre-eclampsia ''Pre-eclampsia''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Eclampsia ''Eeclampsia''] [http://www.ncbi.nlm.nih.gov/pubmed/?term=Gestational+Methyldopa ''Gestational Methyldopa'']

	\|}		\|}

Z8600021 at 12:52, 1 Haziran 2019

2019-06-01T12:52:48Z

← Older revision		Revision as of 22:52, 1 Haziran 2019
Line 19:		Line 19:
	\|-bgcolor="F5FAFF"		\|-bgcolor="F5FAFF"
	\|		\|
			* '''Trends in comorbidity, acuity, and maternal risk associated with preeclampsia across obstetric volume settings'''{{#pmid:29478359\|PMID29478359}} "The objective of this study was to characterize morbidity, acuity, and maternal risks associated with preeclampsia across hospitals with varying obstetric volumes. This retrospective cohort analysis used a large administrative data source, the Perspective database, to characterize the risk for preeclampsia from 2006 to 2015. Of 36,985,729 deliveries included, 1,414,484 (3.8%) had a diagnosis of preeclampsia. Of these, 779,511 (2.1%) had mild, 171,109 (0.5%) superimposed, and 463,864 (1.3%) severe preeclampsia. The prevalence of mild, superimposed, and severe preeclampsia each increased over the study period with severe and superimposed preeclampsia as opposed to mild preeclampsia increasing the most proportionately (53.2 and 102.5 versus 10.8%, respectively). The use of antihypertensives used to treat severe range hypertension increased with use of intravenous labetalol increasing 31.5%, 43.2%, and 36.1% at low-, medium-, and high-volume hospitals. Comorbid risk also increased across hospital volume settings as did risk for severe maternal morbidity. Preeclampsia is increasing across obstetric care settings with preeclamptic patients demonstrating increasing comorbid risk, increased risk for severe morbidity, and more frequent need for treatment of acute hypertension."

	* '''Pharmacogenomics of Hypertension and Preeclampsia: Focus on Gene-Gene Interactions'''{{#pmid:29541029\|PMID29541029}} "Hypertension is a leading cause of cardiovascular mortality, but only about half of patients on antihypertensive therapy achieve blood pressure control. Preeclampsia is defined as pregnancy-induced hypertension and proteinuria, and is associated with increased maternal and perinatal mortality and morbidity. Similarly, a large number of patients with preeclampsia are non-responsive to antihypertensive therapy. Pharmacogenomics may help to guide the personalized treatment for non-responsive hypertensive patients."		* '''Pharmacogenomics of Hypertension and Preeclampsia: Focus on Gene-Gene Interactions'''{{#pmid:29541029\|PMID29541029}} "Hypertension is a leading cause of cardiovascular mortality, but only about half of patients on antihypertensive therapy achieve blood pressure control. Preeclampsia is defined as pregnancy-induced hypertension and proteinuria, and is associated with increased maternal and perinatal mortality and morbidity. Similarly, a large number of patients with preeclampsia are non-responsive to antihypertensive therapy. Pharmacogenomics may help to guide the personalized treatment for non-responsive hypertensive patients."

Z8600021 at 12:49, 1 Haziran 2019

2019-06-01T12:49:50Z

← Older revision		Revision as of 22:49, 1 Haziran 2019
Line 2:		Line 2:
	{{Educational Warning}}		{{Educational Warning}}
	==Introduction==		==Introduction==
	Hypertensive disorders of pregnancy (maternal hypertension) can be environmental, genetic or of unknown causes, occurs in 2-3% (some say higher) of all pregnancies and has an increasing incidence associated with obesity. This page mainly focusses on the effects of hypertension on development, rather than the maternal health condition.		Hypertensive disorders of pregnancy (maternal hypertension) can be environmental, genetic or of unknown causes, occurs in 2-3% (some say higher) of all pregnancies and has an increasing incidence associated with obesity. This page mainly focusses on the effects of hypertension on development, rather than the maternal health condition. Pregnancy-induced hypertension is defined as systolic blood pressure greater than 140 mmHg and diastolic blood pressure greater than 90 mmHg.{{#pmid:26158653\|PMID26158653}}

	Hypertension has previously been grouped into 4 classes:{{#pmid:22439030\|PMID22439030}}		Hypertension has previously been grouped into 4 classes:{{#pmid:22439030\|PMID22439030}}
Line 20:		Line 20:
	\|		\|
	* '''Pharmacogenomics of Hypertension and Preeclampsia: Focus on Gene-Gene Interactions'''{{#pmid:29541029\|PMID29541029}} "Hypertension is a leading cause of cardiovascular mortality, but only about half of patients on antihypertensive therapy achieve blood pressure control. Preeclampsia is defined as pregnancy-induced hypertension and proteinuria, and is associated with increased maternal and perinatal mortality and morbidity. Similarly, a large number of patients with preeclampsia are non-responsive to antihypertensive therapy. Pharmacogenomics may help to guide the personalized treatment for non-responsive hypertensive patients."		* '''Pharmacogenomics of Hypertension and Preeclampsia: Focus on Gene-Gene Interactions'''{{#pmid:29541029\|PMID29541029}} "Hypertension is a leading cause of cardiovascular mortality, but only about half of patients on antihypertensive therapy achieve blood pressure control. Preeclampsia is defined as pregnancy-induced hypertension and proteinuria, and is associated with increased maternal and perinatal mortality and morbidity. Similarly, a large number of patients with preeclampsia are non-responsive to antihypertensive therapy. Pharmacogenomics may help to guide the personalized treatment for non-responsive hypertensive patients."

			* '''Review - Pregnancy-Induced hypertension'''{{#pmid:26158653\|PMID26158653}} "Pregnancy-induced hypertension (PIH) complicates 6-10% of pregnancies. It is defined as systolic blood pressure (SBP) greater than 140 mmHg and diastolic blood pressure (DBP) greater than 90 mmHg. It is classified as mild (SBP 140-149 and DBP 90-99 mmHg), moderate (SBP 150-159 and DBP 100-109 mmHg) and severe (SBP ≥ 160 and DBP ≥ 110 mmHg). PIH refers to one of four conditions: a) pre-existing hypertension, b) gestational hypertension and preeclampsia (PE), c) pre-existing hypertension plus superimposed gestational hypertension with proteinuria and d) unclassifiable hypertension. PIH is a major cause of maternal, fetal and newborn morbidity and mortality. Women with PIH are at a greater risk of abruptio placentae, cerebrovascular events, organ failure and disseminated intravascular coagulation. Fetuses of these mothers are at greater risk of intrauterine growth retardation, prematurity and intrauterine death. Ambulatory blood pressure monitoring over a period of 24 h seems to have a role in predicting deterioration from gestational hypertension to PE. Antiplatelet drugs have moderate benefits when used for prevention of PE. Treatment of PIH depends on blood pressure levels, gestational age, presence of symptoms and associated risk factors. Non-drug management is recommended when SBP ranges between 140-149 mmHg or DBP between 90-99 mmHg. Blood pressure thresholds for drug management in pregnancy vary between different health organizations. According to 2013 ESH/ESC guidelines, antihypertensive treatment is recommended in pregnancy when blood pressure levels are ≥ 150/95 mmHg. Initiation of antihypertensive treatment at values ≥ 140/90 mmHg is recommended in women with a) gestational hypertension, with or without proteinuria, b) pre-existing hypertension with the superimposition of gestational hypertension or c) hypertension with asymptomatic organ damage or symptoms at any time during pregnancy. Methyldopa is the drug of choice in pregnancy. Atenolol and metoprolol appear to be safe and effective in late pregnancy, while labetalol has an efficacy comparable to methyldopa. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II antagonists are contraindicated in pregnancy due to their association with increased risk of fetopathy."

	\|}		\|}
	{\| class="wikitable mw-collapsible mw-collapsed"		{\| class="wikitable mw-collapsible mw-collapsed"
Line 26:		Line 29:
	\| [[File:Mark_Hill.jpg\|90px\|left]] {{Most_Recent_Refs}}		\| [[File:Mark_Hill.jpg\|90px\|left]] {{Most_Recent_Refs}}

	Search term: [http://www.ncbi.nlm.nih.gov/pubmed/?term=Maternal+Hypertension ''Maternal Hypertension''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Gestational+Hypertension ''Gestational Hypertension''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Preeclampsia ''Preeclampsia''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Eclampsia ''Eeclampsia'']		Search term: [http://www.ncbi.nlm.nih.gov/pubmed/?term=Maternal+Hypertension ''Maternal Hypertension''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Gestational+Hypertension ''Gestational Hypertension''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Preeclampsia ''Preeclampsia''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Eclampsia ''Eeclampsia''] [http://www.ncbi.nlm.nih.gov/pubmed/?term=Gestational+Methyldopa ''Gestational Methyldopa'']

	\|}		\|}

Z8600021 at 12:43, 1 Haziran 2019

2019-06-01T12:43:46Z

← Older revision		Revision as of 22:43, 1 Haziran 2019
Line 11:		Line 11:


	~~<center>''Draft Page - Notice removed when completed~~.''<~~/center~~>		Other developmental abnormalities of development, such as {{hypospadias}} have been associated with maternal hypertension.{{#pmid:27570224\|PMID27570224}}
			<br>

	{{Environmental}}		{{Environmental}}

Line 50:		Line 49:

	===Reviews===		===Reviews===
			{{#pmid:28793357}}

			{{#pmid:26158653}}

	{{#pmid:21333604}}		{{#pmid:21333604}}

Z8600021 at 05:22, 7 March 2019

2019-03-07T05:22:38Z

← Older revision		Revision as of 15:22, 7 March 2019
Line 27:		Line 27:
	\| [[File:Mark_Hill.jpg\|90px\|left]] {{Most_Recent_Refs}}		\| [[File:Mark_Hill.jpg\|90px\|left]] {{Most_Recent_Refs}}

	Search term: [http://www.ncbi.nlm.nih.gov/pubmed/?term=Maternal+Hypertension ''Maternal Hypertension'']		Search term: [http://www.ncbi.nlm.nih.gov/pubmed/?term=Maternal+Hypertension ''Maternal Hypertension''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Gestational+Hypertension ''Gestational Hypertension''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Preeclampsia ''Preeclampsia''] \| [http://www.ncbi.nlm.nih.gov/pubmed/?term=Eclampsia ''Eeclampsia'']

	~~<pubmed limit=5>Maternal Hypertension</pubmed>~~		\|}

	~~Search term: [http://www.ncbi.nlm.nih.gov/pubmed/?term~~=~~Gestational+Hypertension ''Gestational Hypertension'']~~		{\| class="wikitable mw-collapsible mw-collapsed"
			! Older papers
			\|-
			\| {{Older papers}}

	~~<pubmed limit=5>Gestational Hypertension</pubmed>~~

	~~Search term: [http://www.ncbi.nlm.nih.gov/pubmed/?term=Preeclampsia ''Preeclampsia'']~~

	~~<pubmed limit=5>Preeclampsia</pubmed>~~
	\|}		\|}
	==Gestational Hypertension==		==Gestational Hypertension==

Z8600021 at 12:07, 19 March 2018

2018-03-19T12:07:43Z

← Older revision		Revision as of 22:07, 19 March 2018
Line 20:		Line 20:
	\|-bgcolor="F5FAFF"		\|-bgcolor="F5FAFF"
	\|		\|
			* '''Pharmacogenomics of Hypertension and Preeclampsia: Focus on Gene-Gene Interactions'''{{#pmid:29541029\|PMID29541029}} "Hypertension is a leading cause of cardiovascular mortality, but only about half of patients on antihypertensive therapy achieve blood pressure control. Preeclampsia is defined as pregnancy-induced hypertension and proteinuria, and is associated with increased maternal and perinatal mortality and morbidity. Similarly, a large number of patients with preeclampsia are non-responsive to antihypertensive therapy. Pharmacogenomics may help to guide the personalized treatment for non-responsive hypertensive patients."
	\|}		\|}
	{\| class="wikitable mw-collapsible mw-collapsed"		{\| class="wikitable mw-collapsible mw-collapsed"

Z8600021 at 12:03, 19 March 2018

2018-03-19T12:03:36Z

← Older revision		Revision as of 22:03, 19 March 2018
Line 4:		Line 4:
	Hypertensive disorders of pregnancy (maternal hypertension) can be environmental, genetic or of unknown causes, occurs in 2-3% (some say higher) of all pregnancies and has an increasing incidence associated with obesity. This page mainly focusses on the effects of hypertension on development, rather than the maternal health condition.		Hypertensive disorders of pregnancy (maternal hypertension) can be environmental, genetic or of unknown causes, occurs in 2-3% (some say higher) of all pregnancies and has an increasing incidence associated with obesity. This page mainly focusses on the effects of hypertension on development, rather than the maternal health condition.

	Hypertension has previously been grouped into 4 classes:~~<ref name=~~PMID22439030~~><pubmed>22439030</pubmed></ref>~~		Hypertension has previously been grouped into 4 classes:{{#pmid:22439030\|PMID22439030}}
	# chronic hypertension		# chronic hypertension
	# preeclampsia-eclampsia		# preeclampsia-eclampsia
Line 45:		Line 45:
	This condition is also known as gestational proteinuric hypertension and occurs in occurs in approximately 2 to 4% of all pregnancies. The pathogenesis of eclamptic convulsions remains unknown and women with a history of eclampsia are at increased risk of eclampsia (1-2%) and preeclampsia (22-35%) in subsequent pregnancies. "Magnesium sulfate is the drug of choice for reducing the rate of eclampsia developing intrapartum and immediately postpartum."(see Sibai BM. 2005).		This condition is also known as gestational proteinuric hypertension and occurs in occurs in approximately 2 to 4% of all pregnancies. The pathogenesis of eclamptic convulsions remains unknown and women with a history of eclampsia are at increased risk of eclampsia (1-2%) and preeclampsia (22-35%) in subsequent pregnancies. "Magnesium sulfate is the drug of choice for reducing the rate of eclampsia developing intrapartum and immediately postpartum."(see Sibai BM. 2005).

	Recent research using a large population study in Norway has shown a strong generational association such that daughters of women who had pre-eclampsia during pregnancy had more than twice the risk of pre-eclampsia themselves. The paper concludes "Maternal genes and fetal genes from either the mother or father may trigger pre-eclampsia. The maternal association is stronger than the fetal association. The familial association predicts more severe pre-eclampsia."~~<ref><pubmed>~~16169871~~</pubmed></ref>~~		Recent research using a large population study in Norway has shown a strong generational association such that daughters of women who had pre-eclampsia during pregnancy had more than twice the risk of pre-eclampsia themselves. The paper concludes "Maternal genes and fetal genes from either the mother or father may trigger pre-eclampsia. The maternal association is stronger than the fetal association. The familial association predicts more severe pre-eclampsia."{{#pmid:16169871\|PMID16169871}}

	==References==		==References==
Line 51:		Line 51:

	===Reviews===		===Reviews===
	~~<pubmed></pubmed>~~		{{#pmid:21333604}}
	~~<pubmed></pubmed>~~
	~~<pubmed>21333604</pubmed>~~		{{#pmid:18649616}}
	~~<pubmed>~~18649616~~</pubmed>~~

	===Articles===		===Articles===
	~~<pubmed>~~22925135~~</pubmed>~~		{{#pmid:22925135}}
	~~<pubmed>~~22439030~~</pubmed>~~
	~~<pubmed></pubmed>~~		{{#pmid:22439030}}
	~~<pubmed></pubmed>~~

Z8600021 at 00:15, 27 Ocak 2017

2017-01-27T00:15:47Z

← Older revision		Revision as of 10:15, 27 Ocak 2017
Line 40:		Line 40:
	==Gestational Hypertension==		==Gestational Hypertension==
	Gestational hypertension was previously called pregnancy-induced hypertension (PIH) and is the new onset of hypertension after 20 weeks of gestation.		Gestational hypertension was previously called pregnancy-induced hypertension (PIH) and is the new onset of hypertension after 20 weeks of gestation.


			==Pre-Eclampsia==
			This condition is also known as gestational proteinuric hypertension and occurs in occurs in approximately 2 to 4% of all pregnancies. The pathogenesis of eclamptic convulsions remains unknown and women with a history of eclampsia are at increased risk of eclampsia (1-2%) and preeclampsia (22-35%) in subsequent pregnancies. "Magnesium sulfate is the drug of choice for reducing the rate of eclampsia developing intrapartum and immediately postpartum."(see Sibai BM. 2005).

			Recent research using a large population study in Norway has shown a strong generational association such that daughters of women who had pre-eclampsia during pregnancy had more than twice the risk of pre-eclampsia themselves. The paper concludes "Maternal genes and fetal genes from either the mother or father may trigger pre-eclampsia. The maternal association is stronger than the fetal association. The familial association predicts more severe pre-eclampsia."<ref><pubmed>16169871</pubmed></ref>

	==References==		==References==

Z8600021 at 00:15, 27 Ocak 2017

2017-01-27T00:15:02Z

← Older revision		Revision as of 10:15, 27 Ocak 2017
Line 2:		Line 2:
	{{Educational Warning}}		{{Educational Warning}}
	==Introduction==		==Introduction==
	Hypertensive disorders of pregnancy (maternal hypertension) can be environmental, genetic or of unknown causes, occurs in 2-3% (some say higher) of all pregnancies and has an increasing incidence associated with obesity.		Hypertensive disorders of pregnancy (maternal hypertension) can be environmental, genetic or of unknown causes, occurs in 2-3% (some say higher) of all pregnancies and has an increasing incidence associated with obesity. This page mainly focusses on the effects of hypertension on development, rather than the maternal health condition.

	Hypertension has previously been grouped into 4 classes:<ref name=PMID22439030><pubmed>22439030</pubmed></ref>		Hypertension has previously been grouped into 4 classes:<ref name=PMID22439030><pubmed>22439030</pubmed></ref>

Z8600021 at 00:13, 27 Ocak 2017

2017-01-27T00:13:28Z

← Older revision		Revision as of 10:13, 27 Ocak 2017
Line 29:		Line 29:

	<pubmed limit=5>Maternal Hypertension</pubmed>		<pubmed limit=5>Maternal Hypertension</pubmed>

			Search term: [http://www.ncbi.nlm.nih.gov/pubmed/?term=Gestational+Hypertension ''Gestational Hypertension'']

			<pubmed limit=5>Gestational Hypertension</pubmed>

			Search term: [http://www.ncbi.nlm.nih.gov/pubmed/?term=Preeclampsia ''Preeclampsia'']

			<pubmed limit=5>Preeclampsia</pubmed>
	\|}		\|}
	==Gestational Hypertension==		==Gestational Hypertension==